著作: [西 正暁]/[島田 光生]/[徳永 卓哉]/[東島 潤]/[吉川 幸造]/[柏原 秀也]/[髙須 千絵]/[石川 大地]/[和田 佑馬]/[江藤 祥平]/[良元 俊昭]/Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer./[World Journal of Surgical Oncology]
(英) Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer.
(英) The lymphocyte to C-reactive protein (CRP) ratio (LCR) is an indicator of systemic inflammation and host-tumor cell interactions. The aim of this study was to investigate the prognostic significance of LCR in lower rectal cancer patients who received preoperative chemo-radiotherapy (CRT). Forty-eight patients with lower rectal cancer who underwent CRT followed by curative surgery were enrolled in this study. Routine blood examinations were performed before and after CRT were used to calculate pre-CRT LCR and post-CRT LCR. The median LCR was used to stratify patients into low and high LCR groups for analysis. The correlation between pre- and post-CRT LCR and clinical outcomes was retrospectively investigated. The pre-CRT LCR was significantly higher than the post-CRT LCR (11,765 and 6780, respectively, P < 0.05). The 5-year overall survival rate was significantly higher for patients with high post-CRT LCR compared with low post-CRT LCR (90.6% and 65.5%, respectively, P < 0.05). In univariate analysis, post-CRT LCR, post-CRT neutrophil to lymphocyte ratio, and fStage were significant prognostic factors for overall survival. In multivariate analysis, post-CRT LCR, but not other clinicopathological factors or prognostic indexes, was a significant prognostic factor for overall survival (P < 0.05). Post-CRT LCR could be a prognostic biomarker for patients with lower rectal cancer.
World Journal of Surgical Oncology([BioMed Central Ltd.])
|年月日||必須||2021年 7月 6日|